The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.
Key takeaways:
- Resmed has completed its acquisition of Noctrix Health, a medical device company developing wearable therapeutics for RLS.
- The deal brings Noctrix’s Nidra Tonic Motor Activation (TOMAC) therapy, an FDA De Novo classified, non-invasive treatment, into Resmed’s clinical sleep health portfolio.
- Resmed plans to integrate Noctrix’s technology into its connected devices and digital health solutions to expand patient access and improve care pathways.
Health technology company Resmed has completed its acquisition of Noctrix Health, which expands Resmed’s clinical sleep health portfolio into the treatment of restless legs syndrome (RLS). Upon completion of the acquisition yesterday, announced in April 2026, Noctrix became a wholly owned subsidiary within the Resmed group.
Noctrix’s Nidra Tonic Motor Activation (TOMAC) therapy is an FDA De Novo classified, noninvasive, nonpharmacologic treatment. It is designed to reduce symptoms of moderate-to-severe RLS and improve sleep quality in adults who have not found sufficient relief with drug therapy.
The therapy has built a foundation of clinical validation, including 10 peer-reviewed publications and inclusion in the American Academy of Sleep Medicine (AASM) clinical practice guidelines for the treatment of RLS.
“Our acquisition of Noctrix Health marks an important step forward in advancing our 2030 strategy and expanding our clinical sleep health portfolio,” says Mick Farrell, chairman and CEO of Resmed, in a release. “We are excited to welcome the Noctrix team to Resmed and scale solutions that improve lives through better sleep and home health technologies.”
Resmed plans to integrate Noctrix’s technology into its portfolio of connected devices and digital health solutions to help expand access, improve care pathways, and enhance patient outcomes over time.
“Since founding Noctrix, our mission has been to deliver innovative, non-pharmacologic solutions for people living with RLS who have limited treatment options,” says Shri Raghunathan, president and CEO of Noctrix Health, in a release. “Joining Resmed will help us advance that mission, enabling us to expand access to TOMAC therapy and reach more patients with a clinically validated solution that can help meaningfully improve sleep and quality of life.”
